ePrints

Exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease: protocol for a multi-centre, randomised, double blind, parallel group, placebo controlled, Phase 3 trial, The 'Exenatide-PD3' study

Lookup NU author(s): Dr Silvia Del DinORCiD, Professor Alison Yarnall, Professor Lynn RochesterORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Publication metadata

Author(s): Vijiaratnam N, Girges C, Auld G, Chau M, MacLagan K, King A, Skene SS, Chowdhury K, Hibbert S, Morris H, Limousin P, Athauda D, Carroll C, Hu MT, Silverdale M, Duncan GW, Chaudhuri R, Lo C, Del Din S, Yarnall AJ, Rochester L, Gibson R, Dickson J, Hunter R, Libri V, Foltynie T

Publication type: Article

Publication status: Published

Journal: BMJ Open

Year: 2021

Volume: 11

Issue: 5

Online publication date: 28/05/2021

Acceptance date: 12/05/2021

Date deposited: 02/06/2021

ISSN (electronic): 2044-6055

Publisher: BMJ Group

URL: https://doi.org/10.1136/bmjopen-2020-047993

DOI: 10.1136/bmjopen-2020-047993

Altmetrics

Funding

Share